SCHEMBL7659641

SCHEMBL7659641

N#Cc1ccc(C(CN2C(=O)C(CC(=O)N3CCOCC3)N(Cc3cccc4ccccc34)C2=O)n2ccnc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 7/20 0.35
HDAC6 Q9UBN7 1/20 0.35
RAB9A P51151 1/20 0.35
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CCR4 P51679 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
PAX8 Q06710 1/20 0.32
CYP17A1 P05093 1/20 0.32
SSTR5 P35346 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7661123 0.92 USP2 (0.38) CYP19A1HDAC6RAB9AUSP2SMN1; SMN2
SCHEMBL7656246 0.79 FNTA (0.48) FNTAFNTB
SCHEMBL7656235 0.66 FNTA (0.48) HDAC6FNTAFNTB
SCHEMBL7654667 0.65 CYP11B1 (0.51) HDAC6FNTAFNTB
SCHEMBL7653501 0.63 FNTA (0.48) HDAC6FNTAFNTB
SCHEMBL7656322 0.60 FNTA (0.44) HDAC6CCR4FNTAFNTB
SCHEMBL1507781 0.59 CYP19A1 (0.66) CYP19A1CYP17A1
SCHEMBL20886938 0.59 KMT2A (0.64) RAB9AKDM4EMAPT
SCHEMBL9432260 0.59 CYP19A1 (0.58) CYP19A1KDM4EMAPTCYP17A1
SCHEMBL7277970 0.58 KMT2A (0.45) RAB9ASMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6384061-B1 HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS LG CHEMICAL LTD. (KR) 2002-05-07 US claimed
US-6384061-B1 HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS LG CHEMICAL LTD. (KR) 2002-05-07 US disclosed